Altamira Therapeutics Ltd. (NASDAQ:CYTO) Sees Large Decrease in Short Interest

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 82,000 shares, a drop of 54.5% from the August 31st total of 180,200 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average daily volume of 444,400 shares, the short-interest ratio is currently 0.2 days.

Altamira Therapeutics Stock Up 0.4 %

Altamira Therapeutics stock traded up $0.00 during mid-day trading on Thursday, reaching $0.67. 27,332 shares of the company were exchanged, compared to its average volume of 878,089. The business has a fifty day moving average of $0.95 and a 200 day moving average of $1.34. Altamira Therapeutics has a 12-month low of $0.67 and a 12-month high of $17.20.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.